Latest news with #AamalCompanyQ.P.S.C.
Zawya
01-05-2025
- Health
- Zawya
Ebn Sina Medical strengthens commitment to healthcare innovation
Doha: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, and Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy® (Semaglutide 2.4mg) in Qatar. The event was attended by H.E. Mr. Anders Bjørn Hansen, the Ambassador of Denmark to the UAE and Qatar, Aamal Company CEO Mr. Rashid Al Mansoori, in the presence of Mr. Manvendra Singh, General Manager of Novo Nordisk Qatar and Dr. Nayla Mansour, Commercial Director on behalf of Mr. Essam Faragalla, General Manager of Ebn Sina Medical. Wegovy® (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA) indicated for chronic weight management in adults and adolescents ages 12 years and above1, is now available in Qatar. Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide2. Obesity in the Gulf is rapidly unfolding with the highest rates globally3. In Qatar, the obesity crisis is particularly severe, the current prevalence of obesity (body mass index [BMI] ≥ 30 kg/m2) amongst adults in Qatar is estimated to be 41% with a notably higher prevalence amongst women (46%) and, nearly 76% of individuals in Qatar are classified as overweight; this places Qatar among the top 10 highest obesity rates in the world4,5,. The high rates of obesity and overweight in Qatar are linked to the high-country overall rates of related chronic conditions such as pre-diabetes, diabetes and cardiovascular diseases (CVDs) 6. The active ingredient in Wegovy®, Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness 1,7. Wegovy® is indicated as adjunct to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m2) or with overweight (BMI ≥ 27 kg/m2) in the presence of at least one weight-related comorbidity.1 As per clinical research, Wegovy® on top of diet and exercise delivers 17% mean weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss 1,8,9,10. Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, Glycemic parameters & C-reactive protein. 1,10,11,12 The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Semaglutide 2.4 mg resulted in a statistically significant 20% risk reduction in Major Adverse Cardiovascular Events (MACE) in people with overweight or obesity and established CVD, without T2DM1,15. Besides its indication in adults, Wegovy® is also approved as the first and only once weekly GLP-1 receptor agonist (GLP-1RA) for chronic weight management in adolescents with obesity from the age of 12 years1. This innovation may help transform the medical management of adolescent obesity in Qatar, where nearly 20% of children and adolescents are affected.6;11 During the event, Mr. Rashid bin Ali Al Mansoori, Aamal Company CEO, welcomed the attendees and highlighted this major step forward in addressing this public health challenge. He emphasized Aamal's commitment to advancing healthcare innovation and infrastructure in Qatar, through its subsidiaries such as Ebn Sina Medical in alignment with the country's National Health Strategy and Vision 2030, and reaffirmed Aamal's dedication to supporting access to the latest healthcare solutions that can positively impact the lives of individuals and the health of our wider community. From Novo Nordisk's side, Mr. Manvendra Singh, General Manager Novo Nordisk Qatar said: 'At Novo Nordisk, we are proud to bring over 100 years of global leadership in chronic disease management and 25 years of dedicated obesity research to Qatar. The availability of Wegovy® marks a significant step in addressing obesity as a serious, chronic disease. As Qatar continues to face high rates of obesity, diabetes, and cardiovascular disease, our collaboration with Ebn Sina is vital. Together, we are committed to strengthening the healthcare landscape and improving patient outcomes through innovative, science-driven solutions.' Ebn Sina Medical General Manager Mr. Essam Faragalla added: 'At Ebn Sina Medical, we are committed to ensuring that the people of Qatar have access to world-class healthcare solutions. This partnership with Novo Nordisk marks a significant milestone in our journey to address the rising prevalence of obesity and related health complications in the country. We enjoy a long-standing relationship with Novo Nordisk and share a unified vision to prioritize patient-centric care. The introduction of Wegovy® reflects our continuous drive to deliver innovative treatments and reinforces our role as a trusted healthcare partner aligned with Qatar's National Health Strategy.' Prof. Usama ALAlami; Head of Medical; Novo Nordisk Qatar highlighted: 'Obesity is the leading cause for many complications and it's the main driver of the diabetes epidemic in Qatar, accounting for 57.5% of diabetes 2 Diabetes (T2DM) and cardiovascular diseases (CVDs) are the greatest contemporary health challenges globally, and there is an urgent need to prevent future increase in new cases and new complications of obesity13. Data on Semaglutide 2.4mg® are reassuring with clinically significant weight loss in people with obesity or overweight. Based on trials' outcome, 80% of those who were with pre-diabetes regressed to normoglycemia9, which suggests that Semaglutide 2.4 mg could help prevent T2D in high-risk people with obesity or overweight'.8,1 About Ebn Sina Medical: Ebn Sina Medical,is a subsidiary of Aamal Company, and it is considered a leading supplier of pharmaceutical supplies, hospital supplies, and health products to consumers in Qatar, with contracts with more than 70 leading international healthcare manufacturers from more than 20 countries. Ebn Sina Medical also operates a chain of pharmacies bearing the name Ebn Sina Pharmacy and three-Foot Care Centers. Ebn Sina Medical has successfully established several strategic partnerships with suppliers, which has enabled the company to diversify its service offering in terms of generic and biosynthetic drugs. Ebn Sina Medical continues to innovate and drive efficiency installing a robot at its warehouse to enable drugs to be handled quickly and accurately. Please visit About Aamal Company Q.P.S.C Aamal is one of the region's most diversified conglomerates and has been listed on the Qatar Stock Exchange since December 2007. As of x May 2025, the Company had market capitalisation of QAR xxbn (US$ xxbn). Aamal's operations are widely diversified and comprise 32 active business units (subsidiaries and joint ventures) with market leading positions in the key industrial, retail, property, managed services, and medical equipment and pharmaceutical sectors, thereby offering investors a high quality and balanced exposure to Qatar's wider economic growth and development. For further information on Aamal Company, please refer to the corporate website: About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 69,000 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contact Aamal Company: Laura Ackel Corporate Communications Officer Email: Contact Novo Nordisk Email: ( References: Wegovy® [summary of product characteristics]. Approved in Qatar October 2024 World Obesity federation. Available at: Accessed on 26 September 2024. World Health Organization. Global Health Observatory (GHO) data. Overweight and obesity. [cited 2020 05 August]. World Obesity Federation. World Obesity Atlas 2024. London: World Obesity Federation, 2024. Accessed on 29 September 2024. Haj Bakri, A. et al. Chronic disease risk factor surveillance: Qatar STEPS report 2012. Qatar: The Supreme Council of Health. Obesity in Qatar: current and future strategies, Taheri, Shahrad et al. The Lancet Diabetes & Endocrinology, Volume 9, Issue 9, 561 – 562, 2021. Anam, M., Maharjan, S., Amjad, Z., et al. (2022). Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus, 14(12), e32610. Colin IM, Gérard KM. Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer? touchREV Endocrinol. 2022 Jun;18(1):35-42. doi: 10.17925/EE.2022.18.1.35. Epub 2022 Jun 15. PMID: 35949360; PMCID: PMC9354513 Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11): 989-1002. D Weghuber et al, N Engl J Med 2022;387:2245-2257, DOI: 10.1056/NEJMoa2208601, VOL. 387 NO. 24 Awad SF, O'Flaherty M, Critchley J, Abu-Raddad LJ. Forecasting the burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. Diabetes Research and Clinical Practice 2018;137:100-8 Qatar National Diabetes Strategy; (Accessed 14 Sep 2024) Roth GA et al. J Am Coll Cardiol 2020;76:2982–3021 Lincoff AM et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232.
Zawya
10-04-2025
- Business
- Zawya
The Assembly approved to distribute 6% dividend to shareholders
A robust performance in 2024 with sustained strategic progress and continued diversification Doha – Qatar: ' Aamal Company Q.P.S.C.' (Aamal), one of the region's most diversified companies, held its Annual Ordinary and Extra-Ordinary General Assembly Meeting, after the quorum was achieved on Wednesday, 9 April 2025 at JW Marriott Marquis City Center Doha Hotel at Al Sidra Ballroom. On behalf of H.E. Sheikh Faisal bin Qassim Al Thani - Chairman of Aamal Company – the deputy CEO, H.E. Sheikh Tamim bin Faisal Qassim Al Thani, welcomed the attendees stating: In the name of Allah, the Most Gracious, the Most Merciful. Distinguished guests, Prior to commencing with the meeting agenda, and on behalf of the Chairman of the Board of Directors, H.E. Sheikh Faisal bin Qassim Al Thani, it is my pleasure to welcome you to the Ordinary and Extraordinary General Assembly Meeting of Aamal Company. Looking at Aamal Company's annual report, we thank Allah that the Company was able to achieve positive results during the year 2024. This impressive achievement was due to the diversification strategy adopted by the Company, its ability to seize various opportunities, the efficiency of the management team, the strength of the Qatari economy, and the commitment of our seasoned government under the leadership of H. H. Sheikh Tamim bin Hamad Al Than in providing a secure and stable investment climate. We always strive for growth and to deliver the best for all stakeholders. I would like to take this opportunity to thank our shareholders for their continued trust, the esteemed members of the Board of Directors, the executive management, and all our employees for their efforts. We look forward to achieving even greater success in 2025, God willing. The full report will be presented by the CEO of Aamal Company, Mr. Rashid bin Ali Al Mansoori. Thank you for your attendance. After the quorum was achieved, the Assembly proceeded to discuss the items on the agenda of the Extra Ordinary General Assembly meeting as follows: To discuss and approve the amendments proposed on the Articles of Association of Aamal Company Q.P.S.C. in accordance with the provisions of the Corporate Governance Law and the Commercial Companies Law. The Assembly approved the amendments proposed on the Articles of Association of Aamal Company Q.P.S.C. in accordance with the provisions of the Corporate Governance Law and the Commercial Companies Law. In the event that the General Assembly approves Item No. (1) as set out above, to authorize the Chairman of the Board, Sheikh Faisal Qassim Al Thani, to sign the new Articles of Association for the purposes of authenticating them by the relevant authorities, and to approve the Chairman to authorize Company staff to undertake the necessary steps to complete the authentication and registration of the new Articles of Association with the relevant authorities. The Assembly approved the proposal to authorize the Chairman of the Board, Sheikh Faisal Qassim Al Thani, to sign the new Articles of Association for the purposes of authenticating them by the relevant authorities, and to approve the Chairman to authorize Company staff to undertake the necessary steps to complete the authentication and registration of the new Articles of Association with the relevant authorities. Accordingly, the Extraordinary General Assembly meeting was concluded. The Assembly then proceeded to discuss the items on the agenda of the Ordinary General Assembly meeting as follows: To hear and approve the Chairman's report on the Company's activities and the financial position for the financial year ended 31 December 2024 and to hear the Company's future business plan. Mr. Rashid bin Ali Al Mansoori, the CEO of Aamal Company, delivered the Chairman's report as follows: 'Esteemed Shareholders, It is my privilege, on behalf of the Board of Directors, to present Aamal Company's Annual Report for 2024. This report reflects our company's strong performance and the resilience of our strategy, which has driven growth and kept us on course despite the challenges of an evolving and dynamic market. I would like to take this opportunity to extend my sincere gratitude to our outgoing board members for their invaluable contributions to Aamal's success. Their guidance and dedication have played a pivotal role in shaping the company's journey. I am also deeply grateful for the wise leadership of H.H. Sheikh Tamim bin Hamad Al Thani, the Amir of the State of Qatar, whose vision and policies continue to foster a dynamic and resilient economy. Qatar's strong governance, strategic investments, and commitment to economic diversification provide a solid foundation for long-term, sustainable growth—one that Aamal is well-positioned to contribute to and benefit from. I am pleased to announce a robust set of results for Aamal in 2024, delivering an impressive 18% rise in year-on-year total net profit as well as a 1.1% increase in total revenue. Throughout the year, we successfully navigated fluctuating market dynamics while remaining agile to new opportunities and challenges, recording solid performances across our segments, particularly Industrial Manufacturing and Managed Services. These results are a testament to the resilience of Aamal's diversified business model, the adept leadership of our management teams, along with our sustained strategic focus on optimising operational efficiency and investing in high-growth sectors. Qatar's 2025 budget is fully aligned with the nation's strategic vision to foster economic diversification within the framework of the Qatar National Vision 2030. The country's GDP is projected to grow by 2.4% in 2025, driven by increased investment, private and public consumption, and growing hydrocarbon output. The North Field LNG expansion project will continue to support medium-term growth, while non-oil activity remains the main driver of economic expansion, fueled by government investments in infrastructure, healthcare, and energy. As a leading player in industrial manufacturing, trading, and managed services, Aamal is well positioned to capitalize on these emerging opportunities and contribute meaningfully to Qatar's economic transformation. Looking ahead, I am confident that Aamal's strong financial position and market leadership across key sectors provide a solid foundation for continued growth in Qatar and beyond. Our strategic focus remains on delivering value to all stakeholders, whether through operational excellence, business expansion, or sustainable investments that align with Qatar's economic ambitions. As we build on this strong performance, we remain committed to enhancing our diverse portfolio, strengthening our partnerships, and supporting the long-term development of the Qatari economy. Finally, I would like to express my sincere appreciation to our employees, management team, and board members for their unwavering dedication and expertise, which continue to drive Aamal's success. In recognition of our strong results, I am pleased to propose a 6% dividend for shareholder approval at today's assembly meeting.' Faisal bin Qassim Al Thani , Chairman, Aamal Company. The General Assembly approved the Chairman's report on the Company's activities and the financial position for the financial year ended 31 December 2024, and the Company's future business plan. To hear and approve the External Auditor's report on the Company's Consolidated Financial Statements for the financial year ended 31 December 2024. The General Assembly approved the External Auditor's report on the Company's Consolidated Financial Statements for the financial year ended 31 December 2024. To discuss and approve the Company's Consolidated financial statements for the financial year ended 31 December 2024. The General Assembly approved the Company's Consolidated financial statements for the financial year ended 31 December 2024. Financial Highlights Total Revenue up 1.1% to QAR 2,100.8m (2023: QAR 2,077.2m) Gross Profit up 3.2% to QAR 515.4m (2023: QAR 499.6m) Net Profit attributable to Aamal equity holders up 17.7% to QAR 432.5m (2023: QAR 367.5m) Reported earnings per share increased 17.7% to QAR 0.069 (2023: QAR 0.058) Net capital expenditure up 10.8% to QAR 39.5m (2023: QAR 35.7m) Gearing increased marginally to 2.52% (2023: 2.41%) To discuss and approve the proposal of the Board of Directors to distribute dividends to current shareholders amounting to 6% of the nominal value of each share of the Company that they own (i.e., QR 0.06 per share). The General Assembly approved the proposal of the Board of Directors to distribute dividends to current shareholders amounting to 6% of the nominal value of each share of the Company that they own (i.e., QR 0.06 per share) in accordance with the QFMA's provisions for dividend distribution. To discuss and approve the Company's Corporate Governance Report for the year ended 31 December 2024. The General Assembly approved the Company's Corporate Governance Report for the year ended 31 December 2024. To discuss and approve the Company's Internal Control over Financial Reporting (ICOFR) Report for the year ended 31 December 2024. The General Assembly approved the Company's Internal Controls over Financial Reporting (ICOFR) Report for the year ended 31 December 2024. To discharge Members of the Board of Directors from their liability for the year ended 31 December 2023 and to decide their remuneration and bonuses. The General Assembly approved discharging Members of the Board of Directors from their liability for the year ended 31 December 2024, and the Assembly approved their remuneration in compliance with the Qatar Financial Markets Authority Governance Code and the Ministry of Commerce and Industry companies law. To vote on the candidates nominated for the Directorship seats on the Board of Aamal for the coming three years term. The shareholders voted to elect the nominees for the Board of Directors for the next three-year term and the following members were elected: H.E. Sheikh Faisal bin Qassim Faisal Al Thani H.E. Sheikh Mohammed Faisal Faisal Qassim Al Thani H.E. Sheikh Jabr Abdulrahman Al Thani H.E. Sheikh Abdullah Hamad Qassim Al Thani H.E. Sheikha Al Jazi Faisal Faisal Qassim Al Thani H.E. Mr. Kamel Mohammed Al Ajla H.E. Mr. Yousef bin Rashid Al Khater H.E. Mr. Ali Hussein Al-Sada H.E. Sheikh Nasser bin Khalid Ahmed Al Thani. To appoint the External Auditor for the Financial Year of 2025 and fix their fees. The General Assembly approved appointing KPMG as the Company's External Auditor for the Financial Year of 2025 and set their fees. About Aamal Company Q.P.S.C. Aamal is one of the region's most diversified companies and has been listed on the Qatar Stock Exchange since December 2007. As at 9 April 2025, the Company had a market capitalisation of QAR 5.54 bn (US$ 1.52 bn). Aamal's operations are widely diversified and comprise 32 active business units (subsidiaries and joint ventures) with market leading positions in the key industrial, retail, property, managed services, and medical equipment and pharmaceutical sectors, thereby offering investors a high quality and balanced exposure to Qatar's wider economic growth and development.
Zawya
09-04-2025
- Business
- Zawya
Qatar: Aamal's Ebn Sina Medical, BeiGene sign strategic partnership
Doha, Qatar: Ebn Sina Medical, a subsidiary of Aamal Company Q.P.S.C. and a leading supplier of pharmaceutical, hospital, and healthcare products in Qatar, has signed a strategic partnership with BeiGene, a global oncology company. The signing ceremony was attended by Aamal's CEO, Rashid bin Ali Al Mansoori, General Manager of Ebn Sina Medical, Dr. Essam Faragalla, and BeiGene's Mohammed Al Kapany, General Manger, Middle East and North Africa Region. Under this agreement, Ebn Sina Medical will serve as the local partner and distributor for BeiGene's range of oncology medicines, enhancing the availability of innovative oncology treatments in Qatar. This collaboration reflects Ebn Sina Medical's commitment to delivering high-quality medicinal products to the local market, benefiting healthcare providers and patients alike. Aamal Company CEO, Rashid bin Ali Al Mansoori, stated: 'This collaboration strengthens Qatar's medical sector by improving patient access to the latest oncology treatments. Ebn Sina Medical's strong market position makes it a trusted partner for renowned global pharmaceutical companies like BeiGene. I look forward to seeing the positive impact this partnership will have on healthcare in Qatar.' General Manager of Ebn Sina Medical, Essam Faragalla, added: 'Partnering with BeiGene marks an important step in expanding access to advanced oncology treatments in Qatar." "Our goal is to support healthcare professionals with the tools they need to improve patient care. Through strategic collaborations like this, we continue to strengthen the healthcare system and enhance treatment options for patients facing complex health challenges.' This strategic alliance aligns with Ebn Sina Medical's mission to enhance patient care by providing access to world-class medicinal products and supporting the evolving needs of Qatar's healthcare sector. General Manager, Middle East and North Africa Region at BeiGene, Mohammed Al Kapany commented: "At BeiGene, we are committed to expanding access to innovative and affordable cancer treatments for more patients around the world." "This partnership with Ebn Sina Medical reflects our shared goal of improving outcomes for people living with cancer in Qatar. Together, we're working to ensure that patients and healthcare providers have access to the high-quality therapies they need — where and when they need them.' © Dar Al Sharq Press, Printing and Distribution. All Rights Reserved. Provided by SyndiGate Media Inc. ( The Peninsula Newspaper
Zawya
16-03-2025
- Business
- Zawya
ECCO Gulf achieves ISO 27001:2022 and ISO 9001:2015 certifications
Doha – Qatar: ECCO Gulf, a leading provider of Business Process Outsourcing (BPO) solutions, and a subsidiary of Aamal Company Q.P.S.C., one of the region's leading diversified companies, proudly announces its achievement of the ISO 27001:2022 and ISO 9001:2015 certifications. This milestone highlights ECCO Gulf's steadfast dedication to data security, quality management, and operational excellence, reinforcing its status as a trusted partner in the BPO industry. ISO 27001:2022 is the globally recognized standard for Information Security Management Systems (ISMS), ensuring that ECCO Gulf adheres to the highest protocols in protecting client data, mitigating cyber threats, and complying with global security regulations. ISO 9001:2015 certifies ECCO Gulf's Quality Management System (QMS), emphasizing a structured approach to service excellence, continuous improvement, and customer satisfaction, which are essential elements for delivering world-class BPO services across diverse industries. This achievement translates to significant benefits for BPO clients, including enhanced data security through robust protection measures, improved operational efficiency via streamlined workflows, alignment with international regulatory standards for risk mitigation, and a continuous commitment to refining processes for exceptional client experiences. Commenting on this accomplishment, Mr. Ehab Abdel Galil, Managing Director of ECCO Gulf, stated: "Obtaining ISO 27001 and ISO 9001 certifications reflects our unwavering commitment to excellence in the BPO industry. In an era where data security and service quality are paramount, these certifications reaffirm our dedication to providing secure, efficient, and top-tier outsourcing solutions. By attaining these certifications and adhering to COPC standards, ECCO Gulf is uniquely positioned to deliver exceptional services, drive superior performance, and enhance customer satisfaction. We take great pride in this achievement and remain focused on setting new industry benchmarks." ECCO Gulf W.L.L is a specialized Business Process Outsourcing and Customer Service company, 51% owned by Aamal Company Q.P.S.C and a subsidiary of the global group Teleperformance, previously known as Majorel. The company designs, builds, and delivers world-class, end-to-end Customer Experience CX solutions for leading digital and vertical businesses, with expertise in tech-augmented front-to-back office customer service, CX consultancy, digital consumer engagement, and a proprietary suite of tailored digital solutions. Distinguished by its simplicity, trust, and drive, ECCO Gulf embodies resilience, agility, attentiveness, and resourcefulness, with employees considered the backbone of the company and selected for their passion and proficiency to foster a dynamic work environment. -Ends-
